US Stock Market Closed

Dashboard

Biogen, Inc. (BIIB)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CEO

Michel Vounatsos

Employees

7,400

Industry

Neurology Biopharmaceuticals

Sector

Healthcare

Headquarters

Cambridge

Exchange

NASDAQ

Summary Stats

Market Cap

43.9B

Revenue

10.4B

Net Income

2.86B

EPS

$19.55

Price-to-Earnings

15.61

Price-to-Book

3.44

Debt-to-Equity

0.95

News

Analyst Ratings

Price targets projected by 27 analysts

High

$450.00

Average

$292.26

Low

$175.00

Ratings calculated by 33 analysts

Buy

12

Hold

17

Sell

4

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.61

Actual

$4.77 +14.7%

Consensus

4.16

Report Date

Year Ago

4.77

Year Ago Change %

Up 0%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites